Postoperative nausea and vomiting  is a common and distressing complication following surgery and anesthesia, leading to patient discomfort, delayed recovery, and increased healthcare costs. Various pharmacological agents are used for its prevention, among which dexamethasone is widely employed. Amisulpride, a selective dopamine  receptor antagonist, has recently emerged as a potential alternative for Post operative nausea and vomiting prophylaxis.

This prospective, randomized, controlled study aims to compare the efficacy and safety of intravenous amisulpride with intravenous dexamethasone in preventing post operative nausea and vomiting in post-surgical patients. Eligible patients undergoing surgery under general anesthesia will be randomly allocated into two groups to receive either intravenous amisulpride or dexamethasone intraoperatively. The primary outcome will be the incidence of postoperative nausea and vomiting within the first twenty four hours after surgery. Secondary outcomes will include severity of nausea, need for rescue antiemetics, and incidence of adverse effects.

The findings of this study are expected to provide evidence regarding the comparative effectiveness and safety of intravenous amisulpride versus dexamethasone, thereby aiding anesthesiologists in selecting optimal prophylactic therapy for Post operative nausea and vomiting